IMAX vs NBIX · P/E 59, rev $352.2M vs P/E 45, rev $1.77B
Imax Corp (IMAX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Imax Corp (IMAX) is a entertainment company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported IMAX revenue for 2024-12-31 was $352.2M. Net income was $32.7M. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. IMAX currently screens at market cap $1.45B and trailing P/E 58.5.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
IMAX currently screens at market cap $1.45B and trailing P/E 58.5. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the IMAX and NBIX stock pages for the full models.
Not investment advice.